argenx SE (FRA:1AE) Short Interest


FRA:1AE argenx SE FRA:1AE
78 GF Score
Price €753.20
GF Value €1,163.40
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is argenx SE Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:1AE vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, argenx SE's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

argenx SE Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's Short Interest distribution charts can be found below:

* The bar in red indicates where argenx SE's Short Interest falls into.


FRA:1AE
78GF Score
argenx SE FRA:1AE
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is argenx SE (FRA:1AE) Overvalued in 2026?

Based on GuruFocus' analysis, argenx SE stock appears to be undervalued. The current stock price of €753.20 is trading 35.3% below its estimated GF Value™ of €1,163.40. GuruFocus considers argenx SE to be Significantly Undervalued.

Key valuation signals for FRA:1AE:

  • Short Interest:
  • GF Value™: €1,163.40 vs. price of €753.20 (35.3% below fair value)
  • GF Score™: 78/100 with 5 warning signs

No single metric tells the full story. See the FRA:1AE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

argenx SE Business Description

Address Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
78GF Score

Get the complete analysis for FRA:1AE

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€753.20
Price
€1,163.40
GF Value